Last update: May 08th 2017
August 31th 2016

EMA’s report on adaptive pathways: little data...

A joint press release issued by ISDB, MiEF and Nordic Cochrane Centre regarding the recently published report on EMA's controversial "adaptive pathways" pilot project. The report includes no new factual data, with no information shared about the drug's indications, type...

December 23th 2015

A PRIME example of how EMA is pushing for...

Joint response of Health Action International (HAI), International Society of Drug Bulletins (ISDB), Mario Negri Institute for Pharmacological Research, Medicines in Europe Forum (MiEF), Nordic Cochrane Centre and Wemos to the European Medicines Agency (EMA) public consultation on the...

October 16th 2015

"Adaptive licensing" or "adaptive pathways":...

Joint briefing paper from Health Action International (HAI), The International Society of Drug Bulletins (ISDB), The Medicines in Europe Forum (MiEF), The Mario Negri Institute for Pharmacological Research, The Nordic Cochrane Centre and WEMOS.

"Adaptive pathways"...

March 20th 2015

European Directive on trade secrets: the JURI...

Joint open Letter to the members of the JURI Committee from the Corporate Europe Observatory (CEO), The Medicines in Europe Forum (MiEF) and The International Society of Drug Bulletins (ISDB) calling on the members of the JURI Committee to ensure, through additional and more ambitious...

for members only

About the International Society of Drug Bulletins (ISDB)


ISDB Information Booklet (october 2008)

dowload PDF English (639 KB)

dowload PDF Spanish (624 KB)

Background

The International Society of Drug Bulletins (ISDB) is a world wide network of bulletins and journals on drugs and therapeutics that are financially and intellectually independent of pharmaceutical industry. It was founded in 1986, with the support of the WHO Regional Office for Europe.
The rationale for the Society is that drug bulletins independent of funding from industry experience problems not faced by editors and publishers of other journals.

Membership

The main requirements for membership are editorial and financial independence, and the quality of the information published. ISDB has two categories of members: full members who meet all membership requirements as set out in the Constitution; and associate members. Associated members are institutions or individuals who do not meet all criteria for membership, but who are sympathetic to the aims of the Society.

 Aims

The overall aim of ISDB is to encourage and assist the development of independent drug bulletins in all countries and to facilitate co-operation amongst them.

ISDB's priorities are:

  • to help all independent drug bulletins achieve the highest professional standards,
  • to support the development of new drug bulletins,
  • to identify independent drug bulletins that are not part of the ISDB network and develop a relationship with them,
  • to encourage members to help health professionals communicate more effectively with consumers,
  • to work with producers of formularies and people in drug information centres,
  • to campaign for drug regulatory authorities to serve public health first and foremost, and
  • to campaign for an independent WHO, ie independent of funding from the pharmaceutical industry.

 

Work of the Society

ISDB holds a General Assembly every three years which provides an excellent forum for members to meet and exchange information. In addition, this allows ISDB members to meet with other attendees, such as producers of formularies, people in drug information centres and other publishers of independent drug and therapeutic information that are not already part of the ISDB network.
To help independent drugs bulletins achieve high professional standards, ISDB organises regional workshops where people working on long established bulletins can share their experience with those starting new ones. Such meetings have been held in Algeria, Hungary, Italy, Japan, Philippines, Italy, Holland and Spain.
To support the development of new drug bulletins, ISDB members also host visits from editors starting up new bulletins to help them gain experience.
ISDB publishes Newsletters which are distributed free to all members and recognised corespondents. This newsletter serves:

  • to keep members and associated members informed of current editorial standards for the development of articles and information,
  • to keep members and associated members informed of current issues and activities, and
  • to facilitate communication between members.

Through its meetings, workshops and newsletters, ISDB also encourages and facilitates discussion on sources of information, organisational structure, ways that bulletins can help health professionals communicate more effectively with consumers, financial support for member bulletins, and any other support for bulletins faced with particular difficulties.
To address public health and drug information issues, ISDB has developed links with many relevant organisations with members being involved in various activities and campaigns. Topics of particular interest are: access to information about medicines, including access to unpublished data held by drug regulatory agencies, the increasing influence of transnational corporations on regulatory authorities and the World Health Organization; and the impact of undue promotion by the pharmaceutical industry.
Other ISDB activities include the exchange of information on new drugs, adverse effects, and drug promotion and regulation.

ISDB - International Society of Drug bullettins

Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it

© 2017